With ruling, Pfizer can escape some claims in legal battle over Chantix carcinogen allegations

Pfizer chalked up a key win in its legal battle surrounding the now-recalled smoking cessation drug Chantix after a New York judge narrowed the scope of the arguments in play.

The consolidated class action lawsuit was brought by Chantix users and payers and levies a number of accusations at Pfizer, including arguments of negligence and unjust enrichment tied to the company's representation of the drug as being free of nitrosamines.